COVID-19 Treatment Remdesivir to Produce in 127 Countries

Monday, 18 May, 2020

It's a multiple-drug strategy based on years of AIDS research.

While remdesivir remains experimental, it has been used to treat patients with COVID-19.

Addressing a news conference, SAPM on health said Pakistan is among the five countries with which the U.S. company has signed licensing agreement for manufacturing the drug.

If enough of the drug isn't available to treat eligible patients, hospitals can use "a lottery system to select a certain proportion of patients who become eligible for the drug", CDPH wrote.

The Department of Health and Human Services on Saturday said Gilead had committed to supply US hospitals with around 607,000 vials of Remdesivir - about 40% of the donation, or enough to treat at least 78,000 patients.

IN officials say they've also received two shipments of the drug and will begin receiving shipments weekly.

It took almost 10 years to show a combination of drugs was needed to treat AIDS.

It may be the most sought-after drugs on our pandemic-ridden planet: remdesivir, the only drug shown to work against coronavirus and be authorized by the U.S. Food and Drug Administration.

During the coronavirus pandemic, hospitals have already been faced with making hard decisions about which patients should get ventilators when there's a shortage.

But in Senate testimony Tuesday, Anthony Fauci, director of the institute, stressed that the study's result for remdesivir "was statistically significant but really modest".

Remdesivir is given by injection.

A week ago, the Japanese Ministry of Health, Labour, and Welfare granted regulatory approval of remdesivir to treat COVID-19 through an exceptional approval pathway.

FDA expanded access programs, sometimes called "compassionate use", represent a process by which patients with immediately life-threatening conditions or a serious disease can gain access to an investigational medical product for treatment outside of clinical trials when no comparable or alternative therapy options are available. In the midst of a pandemic, she added, "I think that we're very conscious of our responsibility as a company, in light of not only the public health crisis that we have, but also the economic crisis that is building up right now". This supply is expected to treat 78,000 COVID-19 patients at US hospitals. "Neither, it reduced the mortality rate nor it reduces the hospitalization time", said the official. Some patients were given the drug while others received a placebo.

Gilead said the drug has improved outcomes for people suffering from the respiratory disease and has provided data suggesting it works better when given in the early stages of infection.